Deborah Harland joined SR One in 2005 to establish the firm’s European investment office. She brings to SR One extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 25 year tenure in the pharmaceutical industry. Deborah is currently a member of the Board of Directors of Asceneuron SA, Atopix Therapeutics, Bicycle Therapeutics, F-star, Mission Therapeutics and VHsquared and is an independent Director on the Board of Cancer Research Technology, the specialist commercialisation and development arm of Cancer Research UK. She  was  previously a member of the Board of Directors of Addex  Pharmaceuticals  (IPO,  SIX Swiss Exchange, 2007),  Pharmakodex Limited (sold to Orexo) and Syntaxin Limited (sold to Ipsen) and an observer on the Boards of Ablynx (IPO, Euronext  Brussels 2007) and 7TM Pharma.  Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from the University of London, and her MBA from Henley Management College.

  Pharmacology  drug developmen